All In Biotech

Drug Trial Radar · NCT06525649

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Aug 21, 2024

Primary completion

Jun 26, 2025

Study completion Jun 26, 2025

Sponsor

Lead sponsor
NeuroPro Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
The Epilepsy Study Consortium
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.

Conditions

  • Photosensitive Epilepsy
  • Epilepsy

Interventions

  • NPT 2042Drug

    NPT 2042 is a new drug being developed as an anti-seizure treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the change in the adjudicated SPR (standard photosensitivity range)Time frame: Through study completion, an average of 4 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials, Inc. (CTI)

    Little Rock, Arkansas

  • Idaho Comprehensive Epilepsy Center

    Boise, Idaho

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.